Share Price and Basic Stock Data
Last Updated: December 10, 2025, 11:33 pm
| PEG Ratio | 2.01 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fervent Synergies Ltd operates within the pharmaceuticals sector, and its recent financial performance illustrates a notable volatility in revenue. For the fiscal year ending March 2025, the company recorded sales of ₹32.46 Cr, a stark recovery from the ₹0.68 Cr reported in March 2022. This upward trajectory is particularly impressive when considering the significant jump from ₹4.63 Cr in March 2023 to ₹24.31 Cr in March 2024. However, the quarterly breakdown reveals an erratic pattern, with sales fluctuating significantly—ranging from a low of ₹0.24 Cr in June 2022 to a peak of ₹26.33 Cr in December 2024. Such variability raises questions about the sustainability of this growth, as it may indicate dependency on specific product launches or market conditions. The company’s ability to maintain this momentum will be crucial as it navigates the competitive landscape of pharmaceuticals.
Profitability and Efficiency Metrics
Fervent Synergies’ profitability metrics present a mixed picture. The operating profit margin (OPM) stood at a robust 57.35% as of the latest reporting, highlighting strong operational efficiency in recent periods. However, this figure masks underlying fluctuations, as the company experienced negative OPMs in prior quarters, notably a staggering -91.25% in March 2024. The net profit margin also demonstrated volatility, improving to 9.09% for the fiscal year 2025 from -52.82% in the previous year. Such significant swings suggest that while the company has made strides in profitability, it remains susceptible to cost pressures and operational challenges. This volatility can be a double-edged sword for investors, as high margins are attractive, yet the inconsistency raises concerns about operational stability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Fervent Synergies appears remarkably strong, particularly in terms of liquidity and solvency. With borrowings reported at a mere ₹0.03 Cr, the company has effectively maintained a debt-free status, which is a significant strength in an industry where financial leverage can often lead to volatility. The current ratio, an astounding 1166.31, suggests a very comfortable liquidity position, indicating that the company can easily meet its short-term obligations. However, the return on equity (ROE) at 7.47% and return on capital employed (ROCE) at the same percentage indicate that the company is generating moderate returns relative to its equity and capital. This performance suggests that while the balance sheet is solid, the efficiency of capital utilization could be improved, which is an essential consideration for potential investors.
Shareholding Pattern and Investor Confidence
Fervent Synergies boasts a strong promoter holding of 74.75%, indicating significant confidence from the company’s founders and management. This level of ownership often translates into a commitment to the company’s long-term vision and stability. The number of shareholders has also been on an upward trend, rising to 3,713 by March 2025, which reflects growing interest from the public. However, it is noteworthy that foreign institutional investors (FIIs) and domestic institutional investors (DIIs) are currently absent, which could suggest that institutional confidence in the stock is still developing. This lack of institutional investment might raise concerns for some retail investors about the stock’s perceived risk profile, especially in an industry subject to regulatory scrutiny and market fluctuations.
Outlook, Risks, and Final Insight
Looking ahead, Fervent Synergies presents both opportunities and challenges. The company’s recent revenue recovery and strong profitability metrics could attract investor interest if sustained. However, the volatility in its financial results poses a significant risk; unexpected fluctuations in sales and profitability could deter potential investors. Additionally, while the absence of debt is a strength, it is essential to examine how the company plans to leverage its equity to drive growth in a competitive market. Investors should also consider the implications of the current shareholding structure, particularly the lack of institutional backing, which may affect stock volatility in the short term. Overall, while Fervent Synergies has demonstrated potential for growth, the journey ahead will require careful navigation of market dynamics and operational challenges to ensure it can deliver consistent performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Fervent Synergies Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 141 Cr. | 112 | 239/84.3 | 31.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,260 Cr. | 390 | 479/192 | 88.2 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.0 Cr. | 44.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 43.8 Cr. | 29.9 | 31.0/17.0 | 104 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,462.95 Cr | 1,157.79 | 51.81 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.24 | 0.23 | 3.27 | 0.89 | 0.32 | 0.32 | 8.83 | 14.85 | 0.34 | 0.39 | 26.33 | 5.40 | 0.68 |
| Expenses | 0.18 | 0.16 | 3.08 | 0.74 | 0.18 | 0.18 | 8.32 | 28.40 | 0.26 | 0.34 | 23.97 | 4.90 | 0.29 |
| Operating Profit | 0.06 | 0.07 | 0.19 | 0.15 | 0.14 | 0.14 | 0.51 | -13.55 | 0.08 | 0.05 | 2.36 | 0.50 | 0.39 |
| OPM % | 25.00% | 30.43% | 5.81% | 16.85% | 43.75% | 43.75% | 5.78% | -91.25% | 23.53% | 12.82% | 8.96% | 9.26% | 57.35% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Profit before tax | 0.05 | 0.06 | 0.18 | 0.14 | 0.13 | 0.13 | 0.50 | -13.60 | 0.07 | 0.04 | 2.35 | 0.49 | 0.38 |
| Tax % | 20.00% | 33.33% | 27.78% | 100.00% | 23.08% | 23.08% | 26.00% | -1.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | 0.05 | 0.05 | 0.14 | 0.00 | 0.10 | 0.09 | 0.37 | -13.41 | 0.07 | 0.04 | 2.35 | 0.50 | 0.38 |
| EPS in Rs | 0.02 | 0.02 | 0.05 | 0.00 | 0.03 | 0.03 | 0.12 | -4.47 | 0.02 | 0.01 | 0.54 | 0.11 | 0.08 |
Last Updated: August 19, 2025, 3:45 pm
Below is a detailed analysis of the quarterly data for Fervent Synergies Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.68 Cr.. The value appears to be declining and may need further review. It has decreased from 5.40 Cr. (Mar 2025) to 0.68 Cr., marking a decrease of 4.72 Cr..
- For Expenses, as of Jun 2025, the value is 0.29 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.90 Cr. (Mar 2025) to 0.29 Cr., marking a decrease of 4.61 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.39 Cr.. The value appears to be declining and may need further review. It has decreased from 0.50 Cr. (Mar 2025) to 0.39 Cr., marking a decrease of 0.11 Cr..
- For OPM %, as of Jun 2025, the value is 57.35%. The value appears strong and on an upward trend. It has increased from 9.26% (Mar 2025) to 57.35%, marking an increase of 48.09%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.38 Cr.. The value appears to be declining and may need further review. It has decreased from 0.49 Cr. (Mar 2025) to 0.38 Cr., marking a decrease of 0.11 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 0.38 Cr.. The value appears to be declining and may need further review. It has decreased from 0.50 Cr. (Mar 2025) to 0.38 Cr., marking a decrease of 0.12 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.08. The value appears to be declining and may need further review. It has decreased from 0.11 (Mar 2025) to 0.08, marking a decrease of 0.03.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:22 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.63 | 3.51 | 3.67 | 39.15 | 5.51 | 16.67 | 7.35 | 2.21 | 0.68 | 4.63 | 24.31 | 32.46 | 32.80 |
| Expenses | 0.50 | 0.53 | 0.66 | 36.47 | 4.41 | 15.26 | 6.90 | 1.93 | 0.86 | 4.15 | 37.08 | 29.47 | 29.50 |
| Operating Profit | 2.13 | 2.98 | 3.01 | 2.68 | 1.10 | 1.41 | 0.45 | 0.28 | -0.18 | 0.48 | -12.77 | 2.99 | 3.30 |
| OPM % | 80.99% | 84.90% | 82.02% | 6.85% | 19.96% | 8.46% | 6.12% | 12.67% | -26.47% | 10.37% | -52.53% | 9.21% | 10.06% |
| Other Income | -0.04 | -0.00 | -0.07 | 0.83 | 0.06 | 0.41 | 0.03 | -0.00 | 0.02 | -0.00 | -0.00 | -0.00 | 0.00 |
| Interest | 0.06 | 0.04 | 0.01 | 0.19 | 0.01 | 0.07 | 0.15 | 0.01 | -0.00 | -0.00 | 0.04 | -0.00 | 0.00 |
| Depreciation | 0.05 | 0.05 | 0.05 | 0.01 | 0.01 | 0.01 | 0.02 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Profit before tax | 1.98 | 2.89 | 2.88 | 3.31 | 1.14 | 1.74 | 0.31 | 0.23 | -0.20 | 0.44 | -12.85 | 2.95 | 3.26 |
| Tax % | 32.83% | 32.53% | 33.68% | 27.19% | 27.19% | 28.74% | 25.81% | 26.09% | 20.00% | 47.73% | -0.00% | -0.00% | |
| Net Profit | 1.33 | 1.95 | 1.91 | 2.41 | 0.83 | 1.23 | 0.24 | 0.17 | -0.24 | 0.23 | -12.84 | 2.95 | 3.27 |
| EPS in Rs | 0.53 | 0.65 | 0.64 | 0.80 | 0.28 | 0.41 | 0.08 | 0.06 | -0.08 | 0.08 | -4.28 | 0.67 | 0.74 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 46.62% | -2.05% | 26.18% | -65.56% | 48.19% | -80.49% | -29.17% | -241.18% | 195.83% | -5682.61% | 122.98% |
| Change in YoY Net Profit Growth (%) | 0.00% | -48.67% | 28.23% | -91.74% | 113.75% | -128.68% | 51.32% | -212.01% | 437.01% | -5878.44% | 5805.58% |
Fervent Synergies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 35% |
| 3 Years: | 263% |
| TTM: | 35% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 65% |
| 3 Years: | 143% |
| TTM: | 125% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 19% |
| 3 Years: | 19% |
| 1 Year: | 13% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -5% |
| 3 Years: | -8% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 3:30 pm
Balance Sheet
Last Updated: December 4, 2025, 2:52 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 25.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 43.75 | 50.00 |
| Reserves | 3.49 | 6.44 | 8.34 | 10.75 | 11.80 | 12.78 | 12.58 | 13.04 | 12.99 | 13.22 | 0.38 | 4.89 | 4.15 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Other Liabilities | 0.72 | 1.02 | 1.02 | 1.49 | 0.39 | 0.71 | 0.82 | 0.70 | 0.14 | 0.23 | 0.14 | 0.14 | 0.10 |
| Total Liabilities | 29.21 | 37.46 | 39.36 | 42.24 | 42.19 | 43.49 | 43.40 | 43.74 | 43.13 | 43.45 | 30.52 | 48.78 | 54.28 |
| Fixed Assets | 0.49 | 0.48 | 0.45 | 1.94 | 3.57 | 17.60 | 17.79 | 17.76 | 16.10 | 16.06 | 7.52 | 7.48 | 7.47 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.00 | 0.00 | 2.16 | 0.00 | 0.97 | 0.72 | 0.28 | 0.57 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 27.72 | 36.98 | 36.75 | 40.30 | 37.65 | 25.17 | 25.33 | 25.41 | 27.03 | 27.39 | 23.00 | 41.30 | 46.81 |
| Total Assets | 29.21 | 37.46 | 39.36 | 42.24 | 42.19 | 43.49 | 43.40 | 43.74 | 43.13 | 43.45 | 30.52 | 48.78 | 54.28 |
Below is a detailed analysis of the balance sheet data for Fervent Synergies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 43.75 Cr. (Mar 2025) to 50.00 Cr., marking an increase of 6.25 Cr..
- For Reserves, as of Sep 2025, the value is 4.15 Cr.. The value appears to be declining and may need further review. It has decreased from 4.89 Cr. (Mar 2025) to 4.15 Cr., marking a decrease of 0.74 Cr..
- For Borrowings, as of Sep 2025, the value is 0.03 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.00 Cr. (Mar 2025) to 0.03 Cr., marking an increase of 0.03 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.10 Cr.. The value appears to be improving (decreasing). It has decreased from 0.14 Cr. (Mar 2025) to 0.10 Cr., marking a decrease of 0.04 Cr..
- For Total Liabilities, as of Sep 2025, the value is 54.28 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 48.78 Cr. (Mar 2025) to 54.28 Cr., marking an increase of 5.50 Cr..
- For Fixed Assets, as of Sep 2025, the value is 7.47 Cr.. The value appears to be declining and may need further review. It has decreased from 7.48 Cr. (Mar 2025) to 7.47 Cr., marking a decrease of 0.01 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 46.81 Cr.. The value appears strong and on an upward trend. It has increased from 41.30 Cr. (Mar 2025) to 46.81 Cr., marking an increase of 5.51 Cr..
- For Total Assets, as of Sep 2025, the value is 54.28 Cr.. The value appears strong and on an upward trend. It has increased from 48.78 Cr. (Mar 2025) to 54.28 Cr., marking an increase of 5.50 Cr..
Notably, the Reserves (4.15 Cr.) exceed the Borrowings (0.03 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 2.13 | 2.98 | 3.01 | 2.68 | 1.10 | 1.41 | 0.45 | 0.28 | -0.18 | 0.48 | -12.77 | 2.99 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 42.61 | 46.37 | 66.12 | 131.60 | 289.03 | 0.00 | 47.30 | 0.00 | 0.00 |
| Inventory Days | 12.16 | 0.00 | 0.00 | 80.66 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Days Payable | 0.00 | 0.00 | ||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 54.77 | 46.37 | 66.12 | 212.26 | 289.03 | 0.00 | 47.30 | 0.00 | 0.00 |
| Working Capital Days | 1,992.93 | 1,589.99 | 2,337.19 | 256.20 | 1,437.48 | 248.95 | 482.20 | 3,260.23 | 14,331.62 | 2,132.45 | 344.58 | 463.17 |
| ROCE % | 7.48% | 9.09% | 8.02% | 7.51% | 2.79% | 4.28% | 1.08% | 0.56% | -0.46% | 1.02% | -34.81% | 7.47% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.68 | -4.28 | 0.08 | -0.08 | 0.06 |
| Diluted EPS (Rs.) | 0.59 | -4.28 | 0.08 | -0.08 | 0.06 |
| Cash EPS (Rs.) | 0.68 | -4.27 | 0.09 | -0.06 | 0.07 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 11.12 | 10.13 | 14.40 | 14.33 | 14.35 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 11.12 | 10.13 | 14.40 | 14.33 | 14.35 |
| Revenue From Operations / Share (Rs.) | 7.42 | 8.10 | 1.54 | 0.22 | 0.73 |
| PBDIT / Share (Rs.) | 0.68 | -4.25 | 0.15 | -0.05 | 0.09 |
| PBIT / Share (Rs.) | 0.67 | -4.27 | 0.14 | -0.06 | 0.08 |
| PBT / Share (Rs.) | 0.67 | -4.28 | 0.14 | -0.06 | 0.07 |
| Net Profit / Share (Rs.) | 0.67 | -4.28 | 0.07 | -0.07 | 0.05 |
| PBDIT Margin (%) | 9.20 | -52.50 | 10.32 | -23.56 | 12.63 |
| PBIT Margin (%) | 9.08 | -52.67 | 9.45 | -29.04 | 10.98 |
| PBT Margin (%) | 9.08 | -52.84 | 9.45 | -29.11 | 10.60 |
| Net Profit Margin (%) | 9.09 | -52.82 | 4.97 | -34.94 | 7.89 |
| Return on Networth / Equity (%) | 6.07 | -42.27 | 0.53 | -0.55 | 0.40 |
| Return on Capital Employeed (%) | 6.05 | -42.00 | 1.01 | -0.45 | 0.56 |
| Return On Assets (%) | 6.05 | -42.08 | 0.52 | -0.55 | 0.39 |
| Asset Turnover Ratio (%) | 0.81 | 0.65 | 0.10 | 0.01 | 0.05 |
| Current Ratio (X) | 1166.31 | 795.38 | 205.92 | 781.01 | 43.67 |
| Quick Ratio (X) | 1166.31 | 795.38 | 205.92 | 781.01 | 43.67 |
| Interest Coverage Ratio (X) | 14935.00 | -304.63 | 2389.00 | -320.60 | 33.04 |
| Interest Coverage Ratio (Post Tax) (X) | 14769.00 | -305.48 | 1152.50 | -474.40 | 21.64 |
| Enterprise Value (Cr.) | 96.89 | 62.69 | 48.33 | 44.11 | 39.38 |
| EV / Net Operating Revenue (X) | 2.99 | 2.58 | 10.44 | 64.84 | 17.81 |
| EV / EBITDA (X) | 32.44 | -4.91 | 101.15 | -275.19 | 140.94 |
| MarketCap / Net Operating Revenue (X) | 2.99 | 2.58 | 10.48 | 65.27 | 20.11 |
| Price / BV (X) | 1.99 | 2.06 | 1.12 | 1.03 | 1.03 |
| Price / Net Operating Revenue (X) | 2.99 | 2.58 | 10.49 | 65.49 | 20.11 |
| EarningsYield | 0.03 | -0.20 | 0.00 | -0.01 | 0.00 |
After reviewing the key financial ratios for Fervent Synergies Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 5. It has increased from -4.28 (Mar 24) to 0.68, marking an increase of 4.96.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 5. It has increased from -4.28 (Mar 24) to 0.59, marking an increase of 4.87.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 3. It has increased from -4.27 (Mar 24) to 0.68, marking an increase of 4.95.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.12. It has increased from 10.13 (Mar 24) to 11.12, marking an increase of 0.99.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.12. It has increased from 10.13 (Mar 24) to 11.12, marking an increase of 0.99.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 7.42. It has decreased from 8.10 (Mar 24) to 7.42, marking a decrease of 0.68.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 2. It has increased from -4.25 (Mar 24) to 0.68, marking an increase of 4.93.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.67. This value is within the healthy range. It has increased from -4.27 (Mar 24) to 0.67, marking an increase of 4.94.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.67. This value is within the healthy range. It has increased from -4.28 (Mar 24) to 0.67, marking an increase of 4.95.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 2. It has increased from -4.28 (Mar 24) to 0.67, marking an increase of 4.95.
- For PBDIT Margin (%), as of Mar 25, the value is 9.20. This value is below the healthy minimum of 10. It has increased from -52.50 (Mar 24) to 9.20, marking an increase of 61.70.
- For PBIT Margin (%), as of Mar 25, the value is 9.08. This value is below the healthy minimum of 10. It has increased from -52.67 (Mar 24) to 9.08, marking an increase of 61.75.
- For PBT Margin (%), as of Mar 25, the value is 9.08. This value is below the healthy minimum of 10. It has increased from -52.84 (Mar 24) to 9.08, marking an increase of 61.92.
- For Net Profit Margin (%), as of Mar 25, the value is 9.09. This value is within the healthy range. It has increased from -52.82 (Mar 24) to 9.09, marking an increase of 61.91.
- For Return on Networth / Equity (%), as of Mar 25, the value is 6.07. This value is below the healthy minimum of 15. It has increased from -42.27 (Mar 24) to 6.07, marking an increase of 48.34.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.05. This value is below the healthy minimum of 10. It has increased from -42.00 (Mar 24) to 6.05, marking an increase of 48.05.
- For Return On Assets (%), as of Mar 25, the value is 6.05. This value is within the healthy range. It has increased from -42.08 (Mar 24) to 6.05, marking an increase of 48.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.81. It has increased from 0.65 (Mar 24) to 0.81, marking an increase of 0.16.
- For Current Ratio (X), as of Mar 25, the value is 1,166.31. This value exceeds the healthy maximum of 3. It has increased from 795.38 (Mar 24) to 1,166.31, marking an increase of 370.93.
- For Quick Ratio (X), as of Mar 25, the value is 1,166.31. This value exceeds the healthy maximum of 2. It has increased from 795.38 (Mar 24) to 1,166.31, marking an increase of 370.93.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 14,935.00. This value is within the healthy range. It has increased from -304.63 (Mar 24) to 14,935.00, marking an increase of 15,239.63.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 14,769.00. This value is within the healthy range. It has increased from -305.48 (Mar 24) to 14,769.00, marking an increase of 15,074.48.
- For Enterprise Value (Cr.), as of Mar 25, the value is 96.89. It has increased from 62.69 (Mar 24) to 96.89, marking an increase of 34.20.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.99. This value is within the healthy range. It has increased from 2.58 (Mar 24) to 2.99, marking an increase of 0.41.
- For EV / EBITDA (X), as of Mar 25, the value is 32.44. This value exceeds the healthy maximum of 15. It has increased from -4.91 (Mar 24) to 32.44, marking an increase of 37.35.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.99. This value is within the healthy range. It has increased from 2.58 (Mar 24) to 2.99, marking an increase of 0.41.
- For Price / BV (X), as of Mar 25, the value is 1.99. This value is within the healthy range. It has decreased from 2.06 (Mar 24) to 1.99, marking a decrease of 0.07.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.99. This value is within the healthy range. It has increased from 2.58 (Mar 24) to 2.99, marking an increase of 0.41.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from -0.20 (Mar 24) to 0.03, marking an increase of 0.23.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fervent Synergies Ltd:
- Net Profit Margin: 9.09%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.05% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 6.07% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 14769
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1166.31
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 25.6 (Industry average Stock P/E: 51.81)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.09%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | B/7-8, Satyam Shopping Centre, Mumbai Maharashtra 400077 | info@ferventsynergies.com http://www.ferventsynergies.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vijay P Thakkar | Chairman |
| Mr. Sanjay P Thakkar | Managing Director |
| Mr. Karan Thakkar | Director & CFO |
| Mr. Nitin Parikh | Independent Director |
| Mr. Rajesh Maheshwari | Independent Director |
| Mrs. Falguni Mehta | Independent Director |
FAQ
What is the intrinsic value of Fervent Synergies Ltd?
Fervent Synergies Ltd's intrinsic value (as of 10 December 2025) is 16.85 which is 10.37% lower the current market price of 18.80, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 93.8 Cr. market cap, FY2025-2026 high/low of 32.0/17.0, reserves of ₹4.15 Cr, and liabilities of 54.28 Cr.
What is the Market Cap of Fervent Synergies Ltd?
The Market Cap of Fervent Synergies Ltd is 93.8 Cr..
What is the current Stock Price of Fervent Synergies Ltd as on 10 December 2025?
The current stock price of Fervent Synergies Ltd as on 10 December 2025 is 18.8.
What is the High / Low of Fervent Synergies Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fervent Synergies Ltd stocks is 32.0/17.0.
What is the Stock P/E of Fervent Synergies Ltd?
The Stock P/E of Fervent Synergies Ltd is 25.6.
What is the Book Value of Fervent Synergies Ltd?
The Book Value of Fervent Synergies Ltd is 10.8.
What is the Dividend Yield of Fervent Synergies Ltd?
The Dividend Yield of Fervent Synergies Ltd is 0.00 %.
What is the ROCE of Fervent Synergies Ltd?
The ROCE of Fervent Synergies Ltd is 7.47 %.
What is the ROE of Fervent Synergies Ltd?
The ROE of Fervent Synergies Ltd is 7.47 %.
What is the Face Value of Fervent Synergies Ltd?
The Face Value of Fervent Synergies Ltd is 10.0.